Skip to main content

Remote Job Finders (RJF)

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
Scroll to top